| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f52c68e4149a6c462b850d4e7cc2b2f9 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-565
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P15-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-57
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P15-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P5-30 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P15-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P15-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P5-30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-567
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-565 |
| filingDate |
2012-11-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c50357ba4959697e475c5d8eb9144f28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_16e8537a79fb8235e882f921bfc17a4e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8ac5dd3bc06407b18206f443d49db39c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_83766e5309d53a0c3fe92b33a9e4c972
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0ef46d726683280d14e9506665ab0e89 |
| publicationDate |
2013-03-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
JP-2013047269-A |
| titleOfInvention |
Use of estradiol valerate or estradiol and dienogest for oral treatment of dysfunctional uterine bleeding in the form of oral contraceptives |
| abstract |
The present invention provides a first oral contraceptive comprising two daily dose units of estradiol valerate or estradiol and dienogest in the above combination of 3 mg estradiol valerate or 3 mg or less estradiol. A second stage comprising two sets of daily dose units, wherein the first set comprises 5 daily dose units of 2 mg estradiol valerate or a combination of 2 mg or less estradiol and 2 mg dienogest. And the second set comprises 17 daily dosage units consisting of 2 mg estradiol valerate or a combination of 2 mg estradiol and 3 mg dienogest; 1 mg estradiol valerate or 1 mg estradiol A third stage consisting of two daily dosage units; and two pharmaceutically harmless placebos Comprising the additional steps of a daily dose unit. [Selection figure] None |
| priorityDate |
2005-10-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |